AACR 2022 | First-in-human trial of MEDI1191 plus durvalumab in patients with advanced solid tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, discusses the first-in-human trial of the locally-injected IL-12 construct, MEDI1191, in combination with durvalumab in patients with advanced solid tumors. The aims of the trial are to investigate safety, tolerability, and efficacy. The trial also aims to determine whether MEDI1191 should be given in a run-in stage, before durvalumab, or given concurrently with durvalumab. Another direction of research is looking into visceral injection of MEDI1191, as hepatic visceral disease is an area of unmet need for patients with solid tumors who respond to PD1 targeted therapies. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.